



COLORADO

**Prescription Drug
Affordability Board**

Division of Insurance

Prescription Drug Affordability Board DRAFT Meeting Minutes

Friday, April 11, 2025; 10 am - 1 pm - Virtual Meeting

[Meeting Recording](#)

Meeting Attendance

Board Members

Dr. Gail Mizner
Dr. Justin VandenBerg
Dr. Amy Gutierrez
Dr. Sami Diab
Ms. Cathy Harshbarger

Board Staff

Lila Cummings
Sophie Thomas
Kate Davidson
Moroj Salih
Callie Shelton
Sagun Sharma
Sara Stultz
Rebecca Walker

Agenda

- Call to Order, Roll Call, Member Updates
- Approval of January 17, 2025 Meeting Minutes
- Approval of February 21, 2025 Meeting Minutes
- Director Updates
- Board Business
 - APCD Data Validation
- Public Comment
- Break
- Board Business
 - Approve Revised *PDAB Policy and Procedures: Policy No. 4 (Affordability Review Policy and Procedure)*
 - Stakeholder Workgroup Discussion
- Public Comment

Call to Order, Roll Call, Member Updates

Dr. Gutierrez called the meeting to order at 10:05 am. All Board members were present, with Ms. Harshbarger joining at 10:22 am. No Board or staff members disclosed any stakeholder meetings.

Approval of January 17, 2025 Meeting Minutes

Dr. Mizner moved and Dr. VandenBerg seconded the motion to approve the January 17 meeting minutes. All three Board members present at the January 17 meeting voted to approve the minutes. Ms. Hashbarger and Dr. Diab did not attend the January 17 meeting, therefore they did not vote to approve the minutes.

[DECISION: January 17 meeting minutes approved at 10:06 am.](#)

**Approval of February 21, 2025 Meeting Minutes**

Dr. VandenBerg moved and Dr. Diab seconded the motion to approve the February 21 meeting minutes. All Board members, with the exception of Ms. Harshbarger, voted to approve the minutes.

DECISION: February 21 meeting minutes approved at 10:07 am.

Director Updates

At 10:08 am, former Prescription Drug Affordability Board (PDAB) Director, Lila Cummings introduced Sophie Thomas as the new PDAB Director. Ms. Thomas provided updates on the upper payment limit (UPL) rulemaking hearing delay and the Amgen v. Mizner et al. case. In addition, Ms. Thomas provided updates on the Cost Benefit Analysis and Regulatory Analysis completed by the Board related to the proposed Enbrel UPL rule, both of which are published on the PDAB website.

Board Business**APCD Data Validation Discussion**

Ms. Cummings presented a summary of the All Payer Claims Database (APCD) data miscategorization that affected the data used by the Board in determining Enbrel, Cosentyx, and Stelara were unaffordable for Colorado consumers.

Ms. Cummings presented validated data from the APCD for Enbrel. After the data presentation, the Board deliberated the changes for Enbrel with the exception of Dr. Diab, who has a conflict of interest with the drug and recused himself. The Board requested a visualization of the changes in the data for Enbrel via percentages. The Board instructed PDAB staff to update the affected data tables in the Affordability Review for Enbrel via an addendum to be presented at their next meeting.

Ms. Cummings presented the validated data from the APCD for Cosentyx. The Board deliberated the changes for Cosentyx with the exception of Dr. Diab, who has a conflict of interest with the drug and recused himself. The Board requested a visualization of changes in the data for Cosentyx via percentages and also more information on the changes in Wholesale Acquisition Cost (WAC) ranges for the drug. The Board instructed PDAB staff to discuss the changes in the data for Cosentyx with Board contractor, PORTAL. The Board also instructed staff to update the affected data tables in the Affordability Review for Enbrel via an addendum.

Ms. Cummings presented the validated data from the APCD for Stelara. The Board deliberated the changes for Stelara. The Board requested a visualization of the changes in the data for Stelara via percentages. The Board instructed PDAB staff to update the affected data tables in the Affordability Review for Stelara via an addendum.

Public Comment

Starting at 11:20 am, the following individuals offered public comment to the Board:

- Amanda Boone - Cystic Fibrosis (CF) United
- Tiffany Westrich-Robertson - AiArthritis
- Sophia Hennessy - Colorado Consumer Health Initiative (CCHI)
- Bridget Seritt - Advocates for Compassionate Therapy Now



COLORADO

Prescription Drug
Affordability Board

Division of Insurance

- Evan Slater - Self

Break

Dr. Mizner called for a 10-minute break from 11:35 to 11:45 am.

Board Business

APCD Data Validation Discussion cont.

The Board summarized its data validation discussion and discussed how to mitigate data issues in the future.

Approve Revised PDAB Policy and Procedures: Policy No. 4 (Affordability Review Policy and Procedure)

Dr. Mizner motioned and Dr. VandenBerg seconded to approve the amendments to PDAB Policy and Procedures: Policy No. 4 as presented by Board staff.

DECISION: At 11:51 am, the Board voted unanimously to approve the amendments. Revised PDAB Policy and Procedures: Policy No. 4 (Affordability Review Policy and Procedure) as presented by Board staff on April 11, 2025 is adopted.

Stakeholder Workgroup Discussion

At 11:52 am, Ms. Thomas discussed a potential work group to consider best practices for gathering patient experience data. The Board discussed who may want to participate in this work group, in addition to the work group considering a voluntary conflict of interest (COI) disclosure for individuals with scientific or medical training. The Board delegated staff to conduct the work group.

Public Comment

Starting at 12:09 pm, the following individuals offered public comment to the Board:

- Jennifer Reinhardt - Self
- Amanda Boone - Cystic Fibrosis (CF) United
- Amy Goodman - Colorado BioScience Association (CBSA)
- Bridget Seritt - Advocates for Compassionate Therapy Now
- Tiffany Westrich-Robertson - AiArthritis
- Harry Gewanter - Let My Doctors Decide Action Network (LMDD)
- Emily Zadvorny - Colorado Pharmacists Society (CPS)

Dr. Mizner adjourned the meeting at 12:34 pm. The next PDAB meeting will be held on Friday, May 23, 2025 at 10 am MT.